Open AccessRussian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19
Author(s) -
И. Е. Чазова,
В. А. Невзорова,
Yu. V. Zhernakova,
М. П. Савенков,
Е. В. Ощепкова,
О Д Остроумова,
О. А. Кисляк,
S. А. Boytsov
Publication year - 2020
Publication title -
sistemnye gipertenzii
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/2075082x.2020.3.200362
Subject(s) - covid-19 , medicine , acute respiratory distress , renin–angiotensin system , pathophysiology of hypertension , coronavirus , intensive care medicine , cardiology , blood pressure , virology , lung , disease , outbreak , infectious disease (medical specialty)
The novel coronavirus infection (COVID-19) caused by the b-coronavirus SARS-CoV-2, and leads to acute respiratory distress-syndrome, has affected more than nineteen million people worldwide, resulting in 0.7 million deaths as of August 2020. The fact that the virus uses angiotensin-converting enzyme 2 as a receptor for entering the target cell, and the high prevalence of hypertension and other cardiovascular diseases among patients with COVID-19, have caused serious discussions on the management of such patients. This consensus of experts from the Russian Medical Society for Arterial Hypertension analyzed the existing data on the relationship between COVID-19 and hypertension, the pathophysiological aspects of the penetration of the virus into target cells and the use of renin-angiotensin-aldosterone system inhibitors in patients with hypertension and COVID-19.